SQZ Biotechnologies Company (SQZB)

OTCMKTS · Delayed Price · Currency is USD
0.0240
0.00 (0.00%)
Apr 27, 2026, 9:30 AM EST
Market Cap707.79K -35.1%
Revenue (ttm)12.12M -44.6%
Net Income-71.64M
EPS-2.43
Shares Out29.49M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume2,686
Open0.0240
Previous Close0.0240
Day's Range0.0240 - 0.0240
52-Week Range0.0228 - 0.0500
Beta0.30
RSI48.06
Earnings Daten/a

About SQZB

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 53
Stock Exchange OTCMKTS
Ticker Symbol SQZB
Full Company Profile

News

STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company

VANCOUVER, British Columbia--(BUSINESS WIRE)--STEMCELL Technologies is pleased to announce the acquisition of substantially all assets of SQZ Biotechnologies Company (SQZ)—a Massachusetts-based biotec...

2 years ago - Business Wire

Asset Sale and Plan of Liquidation and Dissolution Approved by SQZB Shareholders

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB) (the “Company” or “SQZ”) today announced the results for the proposals considered and voted upon by its shareholders at its s...

2 years ago - Business Wire

SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates

WATERTOWN, Mass.WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, today reported third quarter 2023 financial resul...

2 years ago - Business Wire

SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, presented clinical data for three programs focused on the treatme...

2 years ago - Business Wire

SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, today reported second quarter 2023 financial results and recent p...

2 years ago - Business Wire

SQZ Biotechnologies Provides Update on Collaboration with Roche

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB) (the “Company” or “SQZ”) today announced that Roche has determined that it will not exercise its option for HPV 16 positive s...

3 years ago - Business Wire